Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Intellia Therapeutics, Inc. (NTLA) reported a Q3 loss of $1.34 per share, which was better than the Zacks Consensus Estimate of a $1.37 loss. This is an improvement from the $1.38 loss per share reported a year ago.
November 07, 2024 | 3:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intellia Therapeutics reported a Q3 loss of $1.34 per share, better than the expected $1.37 loss, showing an improvement from last year's $1.38 loss.
The better-than-expected earnings report, with a smaller loss than anticipated, is likely to have a positive short-term impact on NTLA's stock price. The improvement from the previous year's loss also adds to the positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100